Industries > Pharma > Ophthalmic Drugs Market Report to 2030

Ophthalmic Drugs Market Report to 2030

Forecasts by Indication (Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs), by Type (Prescription Drugs, OTC Drugs), by Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Ophthalmic Drugs Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 26 November 2020
PAGES: 696
PRODUCT CODE: PHA1022
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA1022 Categories: , Tags: , ,

• Discover the impact of COVID-19 and the subsequent recession/ economic recovery on the Ophthalmic drugs market.
• Realize which global markets are set to be most profitable over the next 10 years for ophthalmic drugs – will the US still dominate this market?
• Unearth which of the new ophthalmic medications (treating glaucoma, waterfall, diabetic retinopathy, and other ophthalmic problems) – along with novel medications – will be the most effective and biggest sellers over the next decade.
• Establish which of the new mergers, acquisitions and collaborations are changing competitive dynamics today.

Which are your competitors and key players doing this year? This report will tell you.

The global market for ophthalmic drugs is increasing yearly. Your competitors in the ophthalmic drugs market are benefiting from key opportunities – what are they and how can you benefit? This report will tell you.

With product approvals over the next decade set to be a key issue facing all competitors in the market – you must discover the essential strategies being implemented by key market players between 2015 and Jan 2021.

Includes crucial sales predictions for the global ophthalmic drugs market and submarkets along with breakdown by region, country and the impact of COVID-19 on those markets. Also included is key segmentation analysis of the ophthalmic drugs market, with forecasts across disease type, infections and distribution channels. Products are forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.

To access the data contained in this document please email contactus@visiongain.com

Leading companies and the potential for market growth
As per Visiongain analysis, global ophthalmic drugs market is estimated to be valued at US$xx in 2021 and is projected to reach at a market value of US$xx by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

Why You Should Buy Visiongain Report only?
The report study aims to explore the market drivers, restraints and also market opportunities facing dermatological drugs product stakeholders in different geographic areas. Also, it identifies trends, gaps, and opportunities in each micro market segment. Finally, this report identifies the major stakeholders, product portfolios, and recent developments in order to draw a competitive landscape for players in this market.

CTA

This unique limited edition report also includes exclusive analysis by

By Indication
• Dry Eye
• Glaucoma Drugs
• Retinal Disorders Drugs
• Allergic, Inflammatory & Infective Drugs
• Others

By Type
• Prescription Drugs
• OTC Drugs

By Distribution Channel
• Hospital Pharmacies
• Drug Stores
• Online Pharmacies

By Region

• North America
– U.S.
– Canada

• Europe
– Germany
– France
– United Kingdom
– Italy
– Spain
– Russia
– Poland
– Rest of Europe

• Asia Pacific
– China
– Japan
– India
– Australia
– South Korea
– Rest of Asia Pacific

• Latin America
– Brazil
– Mexico
– Rest of Latin America

• Middle East & Africa
– Saudi Arabia
– South Africa
– UAE
– Rest of Middle East & Africa

Ophthalmic Drugs Market Report 2020-2030
Need industry data? Please contact us today.

This report includes revenue forecasts over the next decade for the following ophthalmic drugs:
• Eylea
• Lucentis
• Avastin
• Visudyne
• Jetrea
• Pataday
• Vigamox
• Patanol
• TobraDex
• Cravit
• AzaSite
• Acular
• Lumigan and Ganfort
• Xalatan/Xalacom
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
• Azopt
• Trusopt
• Zioptan
• Cosopt
• Tapros/Taflotan
• Restasis
• Refresh
• Hyalein
• Diquas

A company profile gives you the following information:
• Revenue forecast for ophthalmic drugs 5
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), and collaborations, including alliances, partnerships, and joint ventures
• Discussion of a company’s activities and outlook
• Ophthalmic drugs revenue forecasts

Discover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will regulatory changes have?

Research and development activities – assess innovation, trends and possibilities

What is happening in the R&D pipeline for ophthalmic treatments? You see developmental trends, gaining insight into each phase of the ophthalmology R&D pipeline for:
• Dry eye drugs
• Glaucoma drugs
• Allergic, infective and inflammatory drugs
• Retinal disorder drugs
• Other progress in ophthalmology

With analysis of key ophthalmic drugs market players – such as – Novartis, Regeneron, Allergan, Roche, Santen Pharmaceutical Co., Bayer, Pfizer, Senju Pharmaceutical Company Ltd (Senju), Bausch Health Companies Inc., Akorn, Inc., Sun Pharmaceutical Industries Ltd., Aerie Pharmaceuticals Inc, Biogen

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Ophthalmic Drugs Market Report to 2030: Forecasts by Indication (Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs), by Type (Prescription Drugs, OTC Drugs), by Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Ophthalmic Drugs Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Ophthalmic Drugs Market Report to 2030


Download sample pages

Complete the form below to download your free sample pages for Ophthalmic Drugs Market Report to 2030


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories